Stocks recently featured in the blog include: Johnson & Johnson JNJ, Pfizer PFE, Roche RHHBY, AbbVie ABBV and Sanofi SNY. Johnson & Johnson’s third-quarter results were strong as it beat ...
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.
Pfizer, Moderna, Johnson and Johnson COVID-19 vaccines less effective against Omicron, reveals study
Vaccines developed by US drugmakers Pfizer, Moderna, Johnson and Johnson against Covid-19 have proved to be less effective against the new super mutant Omicron variant that has now spread to 77 ...
With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the ...
In fact, Pfizer stock has performed in line with, if not a bit stronger than, pharmaceutical peers such as Merck, Johnson & ...
Now the J&J vaccine is reserved only for those who cannot take the Pfizer or Moderna vaccines, limiting the market. The impact of limited vaccine sales is the primary thing bringing Johnson and ...
Pfizer: Zero hospitalizations or deaths seven days after the second shot. Johnson & Johnson: Zero hospitalizations or deaths 28 days after the single shot. Moderna: trials included more than ...
It has also underperformed the likes of Eli Lilly, Johnson & Johnson, and Amgen. Pfizer’s crash has brought focus on the ...
Johnson & Johnson reports earnings on Tuesday ... The analyst shares his perspective on Pfizer as investors access the company’s role in the post-pandemic market. “When you look at stock ...
Now, remember, this only applies to those persons who got the Pfizer vaccine. I expect we'll know more about Moderna and Johnson and Johnson in the next few weeks. But right now, it only applies ...
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...
Johnson & Johnson’s third-quarter results ... from a range of $9.97-$10.07 to $9.88-$9.98 per share. FDA Approves Pfizer’s New Hemophilia Gene Therapy The FDA granted approval to Pfizer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback